Market Research Logo

Global Tinea Pedis Treatment Market 2017-2021

Global Tinea Pedis Treatment Market 2017-2021

About Tinea Pedis Treatment

Tinea pedis, also known as athlete’s foot, is caused by dermatophyte fungus on foot and can spread to toenails and hands. It is a dermatophyte infection of the soles of the feet and the interdigital spaces. Tinea pedis thrives in warm, humid conditions and is most common among young adult men. Tinea pedis can be transmitted through direct contact with an infected person or by touching surfaces contaminated with the fungus. This fungus lives in warm, moist environments and is found in showers, locker room floors, and swimming pools.

Technavio’s analysts forecast the global tinea pedis treatment market to grow at a CAGR of 3.03% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global tinea pedis treatment market for 2017-2021. To calculate the market size, the report considers the sales of both branded and generic drugs sales.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Tinea Pedis Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • GSK
  • Exeltis USA
  • Valeant
  • Viamet Pharmaceuticals
Other prominent vendors
  • Allergan
  • Almirall
  • Amgen
  • Aqua Pharmaceuticals
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Celgene
  • Dermira
  • Elorac
  • F. Hoffmann-La Roche
  • Galderma
  • Genentech
  • Hexima
  • Hisamitsu Pharmaceutical
  • Incyte
  • Mayne Pharma
  • MediQuest Therapeutics
  • Meiji Seika Pharma
  • Merz Pharmaceuticals
  • Moberg Pharma
  • Mylan Pharmaceuticals
  • NanoBio
  • NovaBiotics
  • Novan
  • Nuvo Research
  • Polichem
  • Promius Pharma
  • Sanofi
  • Seren Pharmaceuticals
  • Sun Pharma
  • Taro
  • Teva Pharmaceutical
  • Theravance Biopharma
  • Tinea Pharmaceuticals
Market driver
  • High unmet needs
  • For a full, detailed list, view our report
Market challenge
  • Increased availability of generics and alternative therapies
  • For a full, detailed list, view our report
Market trend
  • Increased funding for antifungal research
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Tinea Pedis Treatment Market 2017-2021

Technavio recognizes the following companies as the key players in the global tinea pedis treatment market: GSK, Exeltis USA, Valeant, and Viamet Pharmaceuticals.

Other Prominent Vendors in the market are: Allergan, Almirall, Amgen, Aqua Pharmaceuticals, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dermira, Elorac, F. Hoffmann-La Roche, Galderma, Genentech, Hexima, Hisamitsu Pharmaceutical, Incyte, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharmaceuticals, Moberg Pharma, Mylan Pharmaceuticals, NanoBio , NovaBiotics, Novan , Nuvo Research, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Sun Pharma, Taro, Teva Pharmaceutical, Theravance Biopharma, and Tinea Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is increased funding for antifungal research. The growing cases of infectious diseases such as bacterial infection, fungal infection, and viral infection are encouraging vendors to enhance their R&D efforts in this therapy area. As drug development is a cost-intensive process, funding has always been a concern to vendors. This has led to various government and non-governmental institutes to take part in the development of antifungal drugs by providing the required funding to research institutes and companies.”

According to the report, one of the major drivers for this market is high unmet needs. The global tinea pedis treatment market faces significant unmet needs due to low treatment efficacy and prolonged treatment duration. Certain drugs show their efficacy only in the treatment of mild cases of infection. Also, the infection continues to recur as the treatment does not completely cure it. Multiple cycles of unsuccessful treatments increase patient discomfort. This creates a large gap between the demand for and supply of these therapeutics. Thus, the market provides a growth opportunity for vendors with the increasing demand for effective pharmacological therapeutics for fungal infections.

Further, the report states that one of the major factors hindering the growth of this market is increased availability of generics and alternative therapies. The easy availability of alternative treatments for tinea pedis can hamper the market growth. Alternative medications such as tea tree oil, Himalayan crystal salt, apple cider vinegar, garlic, neem oil, oregano oil are used to treat tinea pedis. Also, the preference for alternative therapies such as homeopathy and laser treatments restricts the market growth. Such instances also decrease the therapeutic share of the tinea pedis treatment market. Apart from this, the availability of generic products such as itraconazole, terbinafine, and fluconazole and the patent expiry of many drugs has led to a further decline in market shares.



Companies Mentioned

GSK, Exeltis USA, Valeant, Viamet Pharmaceuticals, Allergan, Almirall, Amgen, Aqua Pharmaceuticals, AstraZeneca, Bayer, Bristol-Myers Squibb, Celgene, Dermira, Elorac, F. Hoffmann-La Roche, Galderma, Genentech, Hexima, Hisamitsu Pharmaceutical, Incyte, Mayne Pharma, MediQuest Therapeutics, Meiji Seika Pharma, Merz Pharmaceuticals, Moberg Pharma, Mylan Pharmaceuticals, NanoBio , NovaBiotics, Novan , Nuvo Research, Polichem, Promius Pharma, Sanofi, Seren Pharmaceuticals, Sun Pharma, Taro, Teva Pharmaceutical, Theravance Biopharma, and Tinea Pharmaceuticals.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Market outline
      • Table Symptoms of tinea pedis
  • Pipeline landscape
    • Table Pipeline analysis
  • Market landscape
    • Market overview
      • Table Global tinea pedis treatment market: Snapshot
      • Table Global tinea pedis treatment market 2016-2021 ($ millions)
      • Table Opportunity analysis: Global tinea pedis treatment market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by ROA
    • Table Global tinea pedis treatment market by ROA 2016
    • Oral
    • Topical
  • Market segmentation by disease type
    • Table Global tinea pedis treatment market by disease type 2016
    • Interdigital tinea pedis
      • Table Global interdigital tinea pedis treatment market 2016-2021 ($ millions)
    • Vesicular tinea pedis
      • Table Global vesicular tinea pedis treatment market 2016-2021 ($ millions)
  • Geographical segmentation
    • Table Global tinea pedis treatment market by geography 2016 and 2021
    • Table Global tinea pedis treatment market by geography 2016-2021 ($ millions)
    • Tinea pedis treatment market in Americas
      • Table Market scenario in Americas
      • Table Tinea pedis treatment market in Americas 2016-2021 ($ millions)
    • Tinea pedis treatment market in EMEA
      • Table Market scenario in EMEA
      • Table Tinea pedis treatment market in EMEA 2016-2021 ($ millions)
    • Tinea pedis treatment market in APAC
      • Table Market scenario of APAC
      • Table Tinea pedis treatment market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
    • Market challenges
  • Market trends
    • Increased funding for antifungal research
    • Increased focus on combination therapies
    • Advent of novel therapies
  • Vendor landscape
    • Competitive scenario
      • Table Competitive structure analysis of global tinea pedis treatment market 2016
      • Table Strategic success factors of companies in global tinea pedis treatment market
  • Key vendor analysis
    • GSK
      • Table GSK: Strength assessment
      • Table GSK: Strategy assessment
      • Table GSK: Opportunity assessment
    • Valeant
      • Table Valeant: Key highlights
      • Table Valeant: Strength assessment
      • Table Valeant: Strategy assessment
      • Table Valeant: Opportunity assessment
    • Exeltis USA
      • Table Exeltis USA: Strength assessment
      • Table Exeltis USA: Strategy assessment
      • Table Exeltis USA: Opportunity assessment
    • Viamet Pharmaceuticals
      • Table Viamet Pharmaceuticals: Strength assessment
      • Table Viamet Pharmaceuticals: Strategy assessment
      • Table Viamet Pharmaceuticals: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report